Substantial improvements in the outcomes of patients with multiple myeloma have created a need for more sensitive diagnostic tests for minimal residual disease (MRD) in this patient population. This Review describes and compares the validity of current clinically used tests for MRD, and highlights the significantly improved outcomes of patients who are known to be MRD negative. Possible opportunities and challenges to the clinical use and widespread implementation of highly sensitive MRD testing are discussed.
- Sham Mailankody
- Neha Korde
- Ola Landgren
